Dimolegin® (60 mg) Given Once Daily in Patients Undergoing Total Hip or Knee Replacement Compared to Enoxaparin
A legfontosabb adatok
- Ki végzi
- Avexima Diol LLC
- Hol
- Oroszország8 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Befejeződött
- Fázis
- 3. fázis
- Résztvevők
- 215 fő vett részt
- Kezdés
- 2024. júl. 22.
- Befejezés
- 2025. jan. 14.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Sodium enoxaparin
- Dimolegin
- Dimolegin placebo
- Sodium enoxaparine placebo
- A regiszteradat frissítve
- 2026. január 16.
Ki vehet részt
- Életkor
- 18 év – 80 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 35 feltétel megnézéseKevesebb
Ki vehet részt
- Men and women between the ages of 18 and 80
- Patients scheduled for unilateral elective total hip or knee arthroplasty
- The patient's voluntary informed consent
- Negative pregnancy test result (for female patients with preserved reproductive potential)
- Patients with reproductive potential should agree to use methods of contraception according to the protocol
Ki nem vehet részt
- Surgery for an acute fracture (<4 weeks)
- Collection of at least one volume unit of donated blood (≥ 450 ml) or blood transfusion during the previous 12 weeks
- Surgery or injury during the last 90 days
- Significant cardiovascular diseases currently or within 6 months prior to screening
- The need for continuous use of antiplatelet drugs, which cannot be discontinued at least 4 days before the start of the investigational therapy
- Systemic therapy with drugs with strong inducers and inhibitors of CYP3A4 and P-glycoprotein, which cannot be discontinued at least 7 days before the start of the investigational therapy
- Participation in another clinical trial currently or within 90 days prior to screening
- Inability to read or write; unwillingness to understand and follow the procedures of the study protocol; non-compliance with the study therapy or procedures
- Increased risk of thrombosis
- Active bleeding or increased risk of bleeding
- Diseases of the digestive system that may disrupt the absorption of the study drug
- Active liver or biliary tract diseases
- Positive test result for HIV, syphilis, hepatitis B and C markers
- The development of trophic disorders of the lower extremities that are not amenable to drug treatment
- Any condition in which, in the opinion of the researcher, surgical intervention or the use of anticoagulants is contraindicated
- Creatinine clearance, calculated according to the Cockcroft-Gault formula, less than 30 ml/min
- Hemoglobin < 105 g/l in women or < 115 g/l in men
- Abnormal results aboratory parameters of the coagulation system (platelets, APTT, prothrombin time, INR) beyond the limits of normal values
- An increase in ALT or ACT ≥ 2 times from the upper limit of normal (ULN) or total bilirubin ≥ 1.5 times from ULN
- Hypersensitivity or contraindications to the administration of Dimolegin®, enoxaparin sodium, unfractionated heparin or warfarin
- Revision or extraction arthroplasty
- Septic arthritis
- The only lower limb
- Current coagulopathy (patient's or his relative's) or congenital thrombophilia
- Body mass index is less than 18.5 or more than 40 kg/m2
- Body weight for women is less than 45 kg, for men less than 57 kg and above 130 kg for both
- Systolic blood pressure > 180 mmHg and/or diastolic blood pressure >110 mmHg
- The need for constant use of parenteral or oral anticoagulants
- Pregnant or breast-feeding women
- Affiliation to a research center, Sponsor, or contractual research organization
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
This clinical study aims to evaluate the efficacy and safety of the anticoagulant Dimolegin® compared to low molecular weight heparin (Clexane®) for the prevention of venous thromboembolic events (VTE) in patients undergoing major joint (hip or knee) replacement surgery. The study will assess the incidence of VTE, VTE-related mortality, and all-cause mortality during different follow-up periods in both treatment groups. Additionally, the study will evaluate the frequency of bleeding events and the incidence, number, and characteristics of all adverse events associated with Dimolegin® and Clexane® therapy.
A vizsgálat 2 csoportja
- 1 (Dimolegin® Group)A vizsgált kezelés
Subgroup 1A (Hip Arthroplasty): Dimolegin® + placebo Clexane® for 35±2 days. Subgroup 1B (Knee Arthroplasty): Dimolegin® + placebo Clexane® for 14±1 days.
Kezelés: Dimolegin és Sodium enoxaparine placebo
- 2 (Clexane® Group)Már használt kezelés, összehasonlításként
Subgroup 2A (Hip Arthroplasty): Clexane® + placebo Dimolegin® for 35±2 days. Subgroup 2B (Knee Arthroplasty): Clexane® + placebo Dimolegin® for 14±1 days.
Kezelés: Sodium enoxaparin és Dimolegin placebo
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Randomized, Double-blind, Double-masked Prospective Multicenter Trial to Evaluate the Efficacy and Safety of the Oral Anticoagulant Dimolegin® Compared With Low Molecular Weight Heparin (Clexane®) as a Means of Preventing VTE in Patients Undergoing Elective Endoprosthetics of Large Joints
- A regiszteradat frissítve
- 2026. január 16.